Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501) - Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with gastric cancer (T-CORE1501)

Tohoku Clinical Oncology Research and Education Society (T-CORE)0 个研究点目标入组 30 人开始时间: 2016年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients who fulfill the following criteria for exclusion are excluded. 1) Received taxane-based regimen. 2) Synchronous double cancer or past history of other cancer within 5 years, except curable carcinoma in situ and skin cancer. 3) Active infection and inflammation. 4) Active hepatitis. 5) Current or past history within 1 year of serious heart disease that requires hospitalization 6) Serious complications or severe complications that require hospitalization for therapy, such as gastrointestinal paresthesia, bowel obstruction, interstitial pneumonia, pulmonary fibrosis, uncontrollable hypertension, diabetes mellitus, renal dysfunction, liver dysfunction, and hepatic cirrhosis. 7) Active gastrointestinal bleeding. 8) Gastrointestinal perforation or histula, artelial embolism within 6 months or venous thromboembolism within 3 months before registration. 9) Receiving medications with psychotropic drugs for mental disorders, or having mental disorders that require medications with psychotropic drugs. 10) Grade 2 or more neuropathy. 11) Effusion that requires drainage. 12) Determined to be inappropriate to enter the study by the responsible researcher or contributing researchers, for any other reasons.

发起方

Tohoku Clinical Oncology Research and Education Society (T-CORE)